- Home
- IPHA vs ACIU Comparison
IPHA vs ACIU Comparison
Compare IPHA & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- ACIU
- Stock Information
- Founded
- IPHA 1999
- ACIU 2003
- Country
- IPHA France
- ACIU Switzerland
- Employees
- IPHA N/A
- ACIU N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- ACIU Health Care
- Exchange
- IPHA Nasdaq
- ACIU Nasdaq
- Market Cap
- IPHA 160.1M
- ACIU 189.1M
- IPO Year
- IPHA 2019
- ACIU 2016
- Fundamental
- Price
- IPHA $1.74
- ACIU $2.04
- Analyst Decision
- IPHA Strong Buy
- ACIU Strong Buy
- Analyst Count
- IPHA 1
- ACIU 1
- Target Price
- IPHA $11.00
- ACIU $12.00
- AVG Volume (30 Days)
- IPHA 11.2K
- ACIU 123.5K
- Earning Date
- IPHA 09-11-2025
- ACIU 08-05-2025
- Dividend Yield
- IPHA N/A
- ACIU N/A
- EPS Growth
- IPHA N/A
- ACIU N/A
- EPS
- IPHA N/A
- ACIU N/A
- Revenue
- IPHA $20,831,349.00
- ACIU $32,014,254.00
- Revenue This Year
- IPHA $209.83
- ACIU N/A
- Revenue Next Year
- IPHA $83.15
- ACIU $533.21
- P/E Ratio
- IPHA N/A
- ACIU N/A
- Revenue Growth
- IPHA N/A
- ACIU 91.20
- 52 Week Low
- IPHA $1.29
- ACIU $1.43
- 52 Week High
- IPHA $3.51
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- IPHA 42.70
- ACIU 54.21
- Support Level
- IPHA $1.71
- ACIU $1.94
- Resistance Level
- IPHA $1.90
- ACIU $2.15
- Average True Range (ATR)
- IPHA 0.08
- ACIU 0.16
- MACD
- IPHA 0.00
- ACIU -0.00
- Stochastic Oscillator
- IPHA 47.62
- ACIU 72.22
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.